These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22614791)

  • 21. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC.
    Kirstein MN; Panetta JC; Gajjar A; Nair G; Iacono LC; Freeman BB; Stewart CF
    Cancer Chemother Pharmacol; 2005 May; 55(5):433-8. PubMed ID: 15818507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients.
    Ting LS; Partovi N; Levy RD; Riggs KW; Ensom MH
    Pharmacotherapy; 2006 Sep; 26(9):1232-40. PubMed ID: 16945044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosing algorithm revisit for busulfan following IV infusion.
    Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter?
    Clemmons AB; Evans S; DeRemer DL; Awan FT
    J Oncol Pharm Pract; 2015 Dec; 21(6):425-32. PubMed ID: 24986792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Estimation of individual pharmacokinetic parameters using maximum a posteriori Bayesian method with D-optimal sampling strategy].
    Ding JJ; Jiao Z; Wang Y
    Yao Xue Xue Bao; 2011 Dec; 46(12):1493-500. PubMed ID: 22375425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative computer simulation study of three different sparse-sampling methods for the estimation of steady-state area under the concentration-time curve (AUC) and maximum concentration (Cmax) in toxicokinetics.
    Mahmood I
    J Pharm Sci; 1997 May; 86(5):579-83. PubMed ID: 9145382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
    Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
    Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
    Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.
    Gibbs JP; Murray G; Risler L; Chien JY; Dev R; Slattery JT
    Cancer Res; 1997 Dec; 57(24):5509-16. PubMed ID: 9407960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
    Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
    Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients.
    de Castro FA; Piana C; Simões BP; Lanchote VL; Della Pasqua O
    Br J Clin Pharmacol; 2015 Oct; 80(4):618-29. PubMed ID: 25819742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the mycophenolic acid exposure estimation methods used in the APOMYGERE, FDCC, and Opticept trials.
    Barraclough KA; Isbel NM; Staatz CE
    Transplantation; 2010 Jul; 90(1):44-51. PubMed ID: 20463644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.
    Trame MN; Bergstrand M; Karlsson MO; Boos J; Hempel G
    Clin Cancer Res; 2011 Nov; 17(21):6867-77. PubMed ID: 21918171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The early plasma concentration of 51Cr-EDTA in patients with cirrhosis and ascites: a comparison of three models.
    Wanasundara SN; Wesolowski MJ; Puetter RC; Burniston MT; Xirouchakis E; Giamalis IG; Babyn PS; Wesolowski CA
    Nucl Med Commun; 2015 Apr; 36(4):392-7. PubMed ID: 25564070
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of limited sampling strategies for estimation of cyclosporine area under the concentration-time curve in hematopoietic stem cell transplant patients.
    Hadjibabaie M; Vazirian I; Iravani M; Moosavi SA; Alimoghaddam K; Ghavamzadeh A; Rezaee S
    Ther Drug Monit; 2011 Dec; 33(6):673-80. PubMed ID: 22011723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium.
    de Winter BC; van Gelder T; Mathot RA; Glander P; Tedesco-Silva H; Hilbrands L; Budde K; van Hest RM
    Ther Drug Monit; 2009 Oct; 31(5):585-91. PubMed ID: 19704401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of treosulfan in pediatric patients undergoing hematopoietic stem cell transplantation.
    Ten Brink MH; Ackaert O; Zwaveling J; Bredius RG; Smiers FJ; den Hartigh J; Lankester AC; Guchelaar HJ
    Ther Drug Monit; 2014 Aug; 36(4):465-72. PubMed ID: 24487253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time.
    Aouam K; Chadli Z; Hammouda M; Fredj NB; Aloui S; May ME; Boughattas N; Skhiri H; Chaabane A
    Ther Drug Monit; 2015 Aug; 37(4):524-30. PubMed ID: 25627405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.